Navigation Links
LSUSHC researchers find potential new target for hypertension treatment
Date:1/30/2009

New Orleans, LA Huijing Xia, PhD, a postdoctoral research associate in the lab of Eric Lazartigues, PhD, Assistant Professor of Pharmacology at LSU Health Sciences Center New Orleans, is the lead author on a paper reporting that a recently identified enzyme in the brain plays a critically important role in the central regulation of blood pressure. The LSUHSC research team showed that Angiotensin-converting enzyme 2 (ACE2) helps preserve the function of a key spontaneous reflex involved in blood pressure regulation and confirms its potential as a target for the prevention or treatment of High Blood Pressure. The research is published in the February 1, 2009 issue of the peer reviewed journal, Hypertension, and the cover of the issue features images of ACE2 expression from the Lazartigues laboratory at LSU Health Sciences Center New Orleans.

The LSUHSC researchers had previously identified ACE2 in the mouse brain in areas involved in the central regulation of cardiovascular function. In this study, they wanted to clarify the role it plays.

Beat-to-beat short term regulation of blood pressure is provided by a spontaneous reflex called the baroreceptor reflex. Receptors in the arteries sense blood pressure and relay the information to the central nervous system where a network of brain stem cells adjust vascular resistance and heart rate. Action of a hypertensive hormone Angiotensin II is known to interfere with that process.

First, the researchers demonstrated that chronically hypertensive mice showed dramatically decreased baroreceptor reflex sensitivity and ACE2 activity. Following treatment with compounds to block both Angiotensin II receptors, the researchers found that by blocking one of these receptors AT1Rs ACE2 activity increased. In order to determine the relationship between AT1Rs blockade and ACE2, as well as the significance of ACE2, the LSUHSC researchers generated a triple-transgenic mouse model with increased ACE2 on a background of chronic hypertension. In this model, they observed that the impaired baroreceptor reflex and other critical functions normalized, as did blood pressure.

"We now have evidence that brain ACE2 plays a critical role in baroreceptor reflex function and , consequently, in the prevention of hypertension," says Dr. Xia.

"Blood pressure" is the force of blood pushing against the walls of the arteries as the heart pumps out blood. If this pressure rises and stays high over time, it can damage the body in many ways. According to the National Institutes of Health, in the United States, about 72 million people have hypertension or High Blood Pressure (HBP). This is about 1 in 3 adults. HBP itself usually has no symptoms. Rarely, headaches may occur. Some people only learn that they have HBP after it causes health problems, such as coronary heart disease, stroke, or kidney failure.

"Beyond our discovery of ACE2, we have now confirmed its potential as a target for the treatment of hypertension and other cardiovascular diseases," concludes Dr. Lazartigues.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-452-9166
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: